Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.

Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA.

Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. doi: 10.1080/13543784.2019.1667333. Epub 2019 Sep 26. Review.

PMID:
31513439
2.

Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.

Hussain RM, Ciulla TA.

Expert Opin Biol Ther. 2016;16(3):365-74. doi: 10.1517/14712598.2016.1131265. Epub 2016 Jan 12. Review.

3.

RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS.

Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A.

Retina. 2016 Jul;36(7):1292-7. doi: 10.1097/IAE.0000000000000876.

4.

Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.

Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K; FAME Study Group.

Ophthalmology. 2014 Oct;121(10):1892-903. doi: 10.1016/j.ophtha.2014.04.019. Epub 2014 Jun 14.

5.

Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.

Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C.

Expert Opin Pharmacother. 2014 May;15(7):953-9. doi: 10.1517/14656566.2014.896899. Epub 2014 Mar 24. Review.

PMID:
24661081
6.

Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.

Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA; READ-2 Study Group.

Eye (Lond). 2014 Mar;28(3):269-78. doi: 10.1038/eye.2013.245. Epub 2013 Nov 22.

7.

Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.

Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG; Diabetic Retinopathy Clinical Research Network.

JAMA Ophthalmol. 2013 Aug;131(8):1033-40. doi: 10.1001/jamaophthalmol.2013.4154.

8.

A practice-based research network focused on comparative effectiveness research in type 2 diabetes management.

Anderson JE, Rhinehart AS, Reid TS, Cuddihy RM, Vlajnic A, Dalal MR, Gemmen E, Johnstone B, Abbaszadeh B, Reed J, Sheller J, Stewart J, Mozaffari E; Diabetes FORWARD Investigators.

Postgrad Med. 2013 May;125(3):172-80. doi: 10.3810/pgm.2013.05.2658.

PMID:
23748518
9.

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.

Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM; Ozurdex PLACID Study Group.

Ophthalmology. 2013 Sep;120(9):1843-51. doi: 10.1016/j.ophtha.2013.02.018. Epub 2013 May 22.

PMID:
23706947
10.

Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.

Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, Campochiaro PA; READ-2 Study Group.

JAMA Ophthalmol. 2013 Feb;131(2):139-45.

PMID:
23544200
11.

Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.

Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane FE; FAMOUS Study Group.

Ophthalmology. 2013 Mar;120(3):583-587. doi: 10.1016/j.ophtha.2012.09.014. Epub 2012 Dec 4.

PMID:
23218184
12.

[Heart failure in Italian intensive cardiac care units: data from the BLITZ-3 survey].

Chinaglia A, Casella G, Scorcu G, Cassin M, Chiarella F, Conte MR, Fradella G, Lucci D, Maggioni AP, Visconti LO; Ricercatori dello Studio BLITZ-3.

G Ital Cardiol (Rome). 2012 Jul-Aug;13(7-8):511-9. doi: 10.1714/1114.12247. Italian.

PMID:
22781378
13.

Impaired ocular blood flow regulation in patients with open-angle glaucoma and diabetes.

Shoshani Y, Harris A, Shoja MM, Arieli Y, Ehrlich R, Primus S, Ciulla T, Cantor A, Wirostko B, Siesky BA.

Clin Exp Ophthalmol. 2012 Sep-Oct;40(7):697-705. doi: 10.1111/j.1442-9071.2012.02778.x. Epub 2012 May 17.

PMID:
22394354
14.

Fibrosis, Enzymatic and Non-Enzymatic Cross-Links in Hypertensive Heart Disease.

Ciulla MM, Paliotti R, Carini M, Magrini F, Aldini G.

Cardiovasc Hematol Disord Drug Targets. 2011;11(2):61-73. Review.

PMID:
22044034
15.

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.

Loftus JV, Sultan MB, Pleil AM; Macugen 1013 Study Group.

Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7498-505. doi: 10.1167/iovs.11-7613.

PMID:
21896838
16.

Patient preferences in the treatment of diabetic retinopathy.

Wirostko B, Beusterien K, Grinspan J, Ciulla T, Gonder J, Barsdorf A, Pleil A.

Patient Prefer Adherence. 2011;5:229-37. doi: 10.2147/PPA.S11972. Epub 2011 May 24.

17.

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.

Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; Macugen 1013 Study Group.

Ophthalmology. 2011 Jun;118(6):1107-18. doi: 10.1016/j.ophtha.2011.02.045. Epub 2011 May 6.

PMID:
21529957
18.

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE; FAME Study Group.

Ophthalmology. 2011 Apr;118(4):626-635.e2. doi: 10.1016/j.ophtha.2010.12.028.

PMID:
21459216
19.

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.

Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA; READ-2 Study Group.

Ophthalmology. 2010 Nov;117(11):2146-51. doi: 10.1016/j.ophtha.2010.08.016. Epub 2010 Sep 19. Erratum in: Ophthalmology. 2011 Jun;118(6):1016. Eliot, Dean [corrected to Eliott, Dean].

PMID:
20855114
20.

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK.

Ophthalmology. 2010 Jun;117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031. Epub 2010 Apr 28.

Supplemental Content

Loading ...
Support Center